Scholar Rock picks lead candidate for muscle diseases

Scholar Rock LLC (Cambridge, Mass.) presented preclinical data from its newly unveiled lead candidate SRK-015, a latent myostatin inhibitor in development to treat muscle diseases.

Scholar Rock plans to develop SRK-015 initially in primary myopathies, though CEO Nagesh Mahanthappa declined to disclose specific indications. He said the company will target "orphan or orphan-like" patient populations which will allow for the fastest route to approval before expanding to a wider range of muscle diseases. The company expects to file an IND by YE16 and have the first clinical data for SRK-015 in 2017. ...